Skip to main content
Clinical Trials/NCT02748343
NCT02748343
Unknown
Phase 1

The Clinical Therapeutic Effects and Safety of Tissue-engineered Bone

Xijing Hospital1 site in 1 country20 target enrollmentNovember 2014

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Bone Defect
Sponsor
Xijing Hospital
Enrollment
20
Locations
1
Primary Endpoint
The scores of bone healing
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to compare use of a tissue-engineered bone to use of a standard allograft bone to treat bone defect in patients. The hypothesis is that use of the tissue-engineered bone is effective and safe to treat the bone defect in patients.

Detailed Description

Patients with the bone defect without infection and sever system diseases will be recruited. The material selected as the scaffold for this study will be a porous β-tricalcium phosphate scaffold (β-TCP) scaffold and scaffold is custom-made according to the size and shape of bone defect after three-dimensional CT scan. Human BMSCs will be obtained and cultured before operation and 3.4×106 cells in 10ml serum-free medium will be seeded onto scaffold to construct the tissue engineered bone graft and co-cultured for two weeks. The implant operation will be carried out under the general anesthesia. The tissue engineered bone graft will be implanted into the bone defect area. The bone defect area will be covered with surrounding soft tissue and muscle to close the wound. Anti-inflammatory, repercussive and analgesic drugs will be used for 1 week. Patient will be hospitalized for 1 to 2 weeks after surgery. Blood routine examination, erythrocyte sedimentation rate, immunoglobulin, autoantibodies and clinical examination will be carried out for signs of pain, swelling, immune rejection and infection. Patient will be evaluated at 3 days,3, 6, 12, 18 and 22 months after operation by radiography; Three-dimensional CT scan will be also performed at regular intervals. The function of the body will be evaluated at regular intervals.

Registry
clinicaltrials.gov
Start Date
November 2014
End Date
December 2020
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Xijing Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • the patients with bone defect and bone nonunion caused by tumor or trauma
  • the length of bone defect in long diaphysis is more than 4cm or more than half of the shaft diameter
  • the size of bone defect is more than 5cmx5cm
  • the patients are unable to use autologous bone graft or other treatments
  • the patients request to use the treatment of tissue-engineered bone
  • Supportive family with willingness to participate in completing questionnaires

Exclusion Criteria

  • Patients with serious diseases such as hemorrhagic disorders, infection, tumor, contagion and so on.
  • Patients who are pregnant
  • Patients with serious abnormal cardiopulmonary function
  • Patients disagree to use the tissue-engineered bone
  • Patients are older than 60 years
  • Patients who are regarded to be unqualified by investigator

Outcomes

Primary Outcomes

The scores of bone healing

Time Frame: within 48 weeks after surgical treatment of bone dect

The scores of bone healing are divided into three kinds: nonhealing: 0; delayed healing: 1; normal healing: 2. The average score of tissue-engineered bone is compared with the score of control group using allograft bone to verify the clinical efficacy of tissue-engineered bone.

the adverse event incidence using tissue-engineered bone and allograft bone

Time Frame: within 24 weeks after surgical treatment of bone dect

the adverse event incidence of tissue-engineered bone is compared with the adverse event incidence of allograft bone to verify the safety of tissue-engineered bone.

Secondary Outcomes

  • The scores of blood routine test(within 48 weeks after surgical treatment of bone dect)
  • The scores of C-reactive protein(within 48 weeks after surgical treatment of bone dect)
  • The scores of the ratio of complement C3 to complement C4(within 48 weeks after surgical treatment of bone dect)
  • The scores of immunoglobulin assay(within 48 weeks after surgical treatment of bone dect)
  • The scores of pain(within 48 weeks after surgical treatment of bone dect)
  • The scores of erythrocyte sedimentation rate(ESR)(within 48 weeks after surgical treatment of bone dect)
  • The scores of duration of hospital stay(within 48 weeks after surgical treatment of bone dect)
  • the scores of time of weight loading after operation(within 48 weeks after surgical treatment of bone dect)
  • The scores of tumorigenesis(within 48 weeks after surgical treatment of bone dect)
  • The scores of treatment course(within 48 weeks after surgical treatment of bone dect)
  • The scores of number of operations(within 48 weeks after surgical treatment of bone dect)
  • The scores of wound healing of soft tissue(within 48 weeks after surgical treatment of bone dect)

Study Sites (1)

Loading locations...

Similar Trials